Orthofix Medical Inc. · Healthcare
Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions, as well as markets regenerative non-tissue biologic solutions derived from synthetic materials. The Global Orthopedics segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
Healthcare
Medical - Devices
1,616
1992-04-24
0.82
Insider Activity

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced a strategic realignment of its Spine leadership team designed to accelerate profitable growth and sharpen execution across its commercial and innovation priorities. The Company also reported preliminary, unaudited net sales results for the first quarter ended March 31, 2026. Spine Leadership Realignment To accelerate decision-making, sharpen leadership accountabi.

JPMorgan Chase and Co. lifted its stake in shares of Orthofix Medical Inc. (NASDAQ: OFIX) by 33.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 258,035 shares of the medical device company's stock after acquiring an additional 64,486 shares during the

Orthofix Medical (NASDAQ: OFIX - Get Free Report) and CVRx (NASDAQ: CVRX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends. Volatility and Risk Orthofix Medical has a beta

Orthofix (OFIX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Orthofix Medical Inc. (NASDAQ: OFIX) breached their fiduciary duties to shareholders. If you currently own Orthofix stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your.

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Orthofix Medical Inc. (NASDAQ: OFIX). If you currently own shares of Orthofix Medical stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=19330 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at case@rosenlegal.com. Why R.
Vitale Lucas
officer: CP&BOO
4,269 SH @ $11.92
2026-03-17
CAPPS VICKIE L
director
2,400 SH @ $12.45
2026-03-10
CAPPS VICKIE L
director
100 SH @ $12.44
2026-03-10
CAPPS VICKIE L
director
2,500 SH @ $12.48
2026-03-09
Andrews Julie
officer: CFO
2,425 SH @ $12.92
2026-03-04
Andrews Julie
officer: CFO
2,363 SH @ $12.55
2026-03-05
Vitale Lucas
officer: CP&BOO
1,171 SH @ $12.92
2026-03-04
Vitale Lucas
officer: CP&BOO
1,141 SH @ $12.55
2026-03-05